title: Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro.
abstract: Inhibition of cytochrome P450IA2 activity is an important adverse effect of quinolone antibacterial agents. It results in a prolonged half-life for some drugs that are coadministered with quinolones, such as theophylline. The objective of the study described here was to define the parameters for quantifying the inhibitory potencies of quinolones against cytochrome P450IA2 in vivo and in vitro and to investigate the relationship between the results of both approaches. Cytochrome P450IA2 activity in vitro was measured by using the 3-demethylation rate of caffeine (500 microM) in human liver microsomes. The inhibitory potency of a quinolone in vitro was determined by calculating the decrease in the activity of cytochrome P450IA2 caused by addition of the quinolone (500 microM) into the incubation medium. The mean values (percent reduction of activity without quinolone) were as follows: enoxacin, 74.9%; ciprofloxacin, 70.4%; nalidixic acid, 66.6%; pipemidic acid, 59.3%; norfloxacin, 55.7%; lomefloxacin, 23.4%; pefloxacin, 22.0%; amifloxacin, 21.4%; difloxacin, 21.3%; ofloxacin, 11.8%; temafloxacin, 10.0%; fleroxacin, no effect. The inhibitory potency of a quinolone in vivo was defined by a dose- and bioavailability-normalized parameter calculated from changes of the elimination half-life of theophylline and/or caffeine reported in previously published studies. Taking the pharmacokinetics of the quinolones into account, it was possible to differentiate between substances with and without clinically relevant inhibitory effects by using results of in vitro investigations. The in vitro test described here may help to qualitatively predict the relevant drug interactions between quinolones and methylxanthines that occur during therapy.
authors.affiliation: Department of Clinical Pharmacology, University Hospital Frankfurt, Federal Republic of Germany.
authors.forename: U
authors.initials: U
authors.lastname: Fuhr
authors.forename: E M
authors.initials: EM
authors.lastname: Anders
authors.forename: G
authors.initials: G
authors.lastname: Mahr
authors.forename: F
authors.initials: F
authors.lastname: Sörgel
authors.forename: A H
authors.initials: AH
authors.lastname: Staib
mesh_terms: D042462:4-Quinolones; D000890:Anti-Infective Agents / Q000009:adverse effects*; D002110:Caffeine / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D019388:Cytochrome P-450 CYP1A2; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000032:analysis; D006801:Humans; D066298:In Vitro Techniques; D008862:Microsomes, Liver / Q000187:drug effects; D010088:Oxidoreductases / Q000032:analysis / Q000037:antagonists & inhibitors*; D013806:Theophylline / Q000008:administration & dosage / Q000032:analysis
chemical_list: D042462:4-Quinolones; D000890:Anti-Infective Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D002110:Caffeine; D003577:Cytochrome P-450 Enzyme System; D013806:Theophylline; D010088:Oxidoreductases; D019388:Cytochrome P-450 CYP1A2; C021183:1,7-dimethylxanthine